Cargando…

Framingham Heart Study genome-wide association: results for pulmonary function measures

BACKGROUND: Pulmonary function measures obtained by spirometry are used to diagnose chronic obstructive pulmonary disease (COPD) and are highly heritable. We conducted genome-wide association (GWA) analyses (Affymetrix 100K SNP GeneChip) for measures of lung function in the Framingham Heart Study. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilk, Jemma B, Walter, Robert E, Laramie, Jason M, Gottlieb, Daniel J, O'Connor, George T
Formato: Texto
Lenguaje:English
Publicado: BMC 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1995616/
https://www.ncbi.nlm.nih.gov/pubmed/17903307
http://dx.doi.org/10.1186/1471-2350-8-S1-S8
_version_ 1782135525154488320
author Wilk, Jemma B
Walter, Robert E
Laramie, Jason M
Gottlieb, Daniel J
O'Connor, George T
author_facet Wilk, Jemma B
Walter, Robert E
Laramie, Jason M
Gottlieb, Daniel J
O'Connor, George T
author_sort Wilk, Jemma B
collection PubMed
description BACKGROUND: Pulmonary function measures obtained by spirometry are used to diagnose chronic obstructive pulmonary disease (COPD) and are highly heritable. We conducted genome-wide association (GWA) analyses (Affymetrix 100K SNP GeneChip) for measures of lung function in the Framingham Heart Study. METHODS: Ten spirometry phenotypes including percent of predicted measures, mean spirometry measures over two examinations, and rates of change based on forced expiratory volume in one second (FEV(1)), forced vital capacity (FVC), forced expiratory flow from the 25(th )to 75(th )percentile (FEF(25–75)), the FEV(1)/FVC ratio, and the FEF(25–75)/FVC ratio were examined. Percent predicted phenotypes were created using each participant's latest exam with spirometry. Predicted lung function was estimated using models defined in the set of healthy never-smokers, and standardized residuals of percent predicted measures were created adjusting for smoking status, pack-years, and body mass index (BMI). All modeling was performed stratified by sex and cohort. Mean spirometry phenotypes were created using data from two examinations and adjusting for age, BMI, height, smoking and pack-years. Change in pulmonary function over time was studied using two to four examinations with spirometry to calculate slopes, which were then adjusted for age, height, smoking and pack-years. RESULTS: Analyses were restricted to 70,987 autosomal SNPs with minor allele frequency ≥ 10%, genotype call rate ≥ 80%, and Hardy-Weinberg equilibrium p-value ≥ 0.001. A SNP in the interleukin 6 receptor (IL6R) on chromosome 1 was among the best results for percent predicted FEF(25–75). A non-synonymous coding SNP in glutathione S-transferase omega 2 (GSTO2) on chromosome 10 had top-ranked results studying the mean FEV(1 )and FVC measurements from two examinations. SNPs nearby the SOD3 and vitamin D binding protein genes, candidate genes for COPD, exhibited association to percent predicted phenotypes. CONCLUSION: GSTO2 and IL6R are credible candidate genes for association to pulmonary function identified by GWA. These and other observed associations warrant replication studies. This resource of GWA results for pulmonary function measures is publicly available at http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?id=phs000007.
format Text
id pubmed-1995616
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher BMC
record_format MEDLINE/PubMed
spelling pubmed-19956162007-10-01 Framingham Heart Study genome-wide association: results for pulmonary function measures Wilk, Jemma B Walter, Robert E Laramie, Jason M Gottlieb, Daniel J O'Connor, George T BMC Med Genet Research BACKGROUND: Pulmonary function measures obtained by spirometry are used to diagnose chronic obstructive pulmonary disease (COPD) and are highly heritable. We conducted genome-wide association (GWA) analyses (Affymetrix 100K SNP GeneChip) for measures of lung function in the Framingham Heart Study. METHODS: Ten spirometry phenotypes including percent of predicted measures, mean spirometry measures over two examinations, and rates of change based on forced expiratory volume in one second (FEV(1)), forced vital capacity (FVC), forced expiratory flow from the 25(th )to 75(th )percentile (FEF(25–75)), the FEV(1)/FVC ratio, and the FEF(25–75)/FVC ratio were examined. Percent predicted phenotypes were created using each participant's latest exam with spirometry. Predicted lung function was estimated using models defined in the set of healthy never-smokers, and standardized residuals of percent predicted measures were created adjusting for smoking status, pack-years, and body mass index (BMI). All modeling was performed stratified by sex and cohort. Mean spirometry phenotypes were created using data from two examinations and adjusting for age, BMI, height, smoking and pack-years. Change in pulmonary function over time was studied using two to four examinations with spirometry to calculate slopes, which were then adjusted for age, height, smoking and pack-years. RESULTS: Analyses were restricted to 70,987 autosomal SNPs with minor allele frequency ≥ 10%, genotype call rate ≥ 80%, and Hardy-Weinberg equilibrium p-value ≥ 0.001. A SNP in the interleukin 6 receptor (IL6R) on chromosome 1 was among the best results for percent predicted FEF(25–75). A non-synonymous coding SNP in glutathione S-transferase omega 2 (GSTO2) on chromosome 10 had top-ranked results studying the mean FEV(1 )and FVC measurements from two examinations. SNPs nearby the SOD3 and vitamin D binding protein genes, candidate genes for COPD, exhibited association to percent predicted phenotypes. CONCLUSION: GSTO2 and IL6R are credible candidate genes for association to pulmonary function identified by GWA. These and other observed associations warrant replication studies. This resource of GWA results for pulmonary function measures is publicly available at http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?id=phs000007. BMC 2007-09-19 /pmc/articles/PMC1995616/ /pubmed/17903307 http://dx.doi.org/10.1186/1471-2350-8-S1-S8 Text en Copyright © 2007 Wilk et al; licensee BioMed Central Ltd. https://creativecommons.org/licenses/by/2.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0 (https://creativecommons.org/licenses/by/2.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Wilk, Jemma B
Walter, Robert E
Laramie, Jason M
Gottlieb, Daniel J
O'Connor, George T
Framingham Heart Study genome-wide association: results for pulmonary function measures
title Framingham Heart Study genome-wide association: results for pulmonary function measures
title_full Framingham Heart Study genome-wide association: results for pulmonary function measures
title_fullStr Framingham Heart Study genome-wide association: results for pulmonary function measures
title_full_unstemmed Framingham Heart Study genome-wide association: results for pulmonary function measures
title_short Framingham Heart Study genome-wide association: results for pulmonary function measures
title_sort framingham heart study genome-wide association: results for pulmonary function measures
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1995616/
https://www.ncbi.nlm.nih.gov/pubmed/17903307
http://dx.doi.org/10.1186/1471-2350-8-S1-S8
work_keys_str_mv AT wilkjemmab framinghamheartstudygenomewideassociationresultsforpulmonaryfunctionmeasures
AT walterroberte framinghamheartstudygenomewideassociationresultsforpulmonaryfunctionmeasures
AT laramiejasonm framinghamheartstudygenomewideassociationresultsforpulmonaryfunctionmeasures
AT gottliebdanielj framinghamheartstudygenomewideassociationresultsforpulmonaryfunctionmeasures
AT oconnorgeorget framinghamheartstudygenomewideassociationresultsforpulmonaryfunctionmeasures